Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHIK
- Development stage
- Unknown
- Lead developer
- Valneva
- Modality
- Vaccines & Immunotherapeutics
01
Overview
CHIK is an abbreviation primarily used for Chikungunya virus and Chikungunya fever, a mosquito-borne viral illness. In the context of drug development, 'CHIK' often refers to the Chikungunya virus or its components when used as an active ingredient in investigational vaccines, such as MV-CHIK and ChAdOx1 Chik, which aim to induce an immune response to prevent infection. It also denotes the Chikungunya virus protease (CHIKVP), a key target for antiviral drug development. The 'chik sign' is a distinct clinical marker of nasal hyperpigmentation associated with Chikungunya fever.
- Other names
- Chikungunya virusChikungunya fever
02
Targets
TLR4 (Toll-like receptor 4)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on CHIK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHIK.